Biogen Inc (BIIB)
194.44
+3.99
(+2.10%)
USD |
NASDAQ |
Apr 19, 16:00
194.44
0.00 (0.00%)
After-Hours: 20:00
Biogen Cash from Operations (TTM): 1.547B for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 1.547B |
September 30, 2023 | 1.360B |
June 30, 2023 | 1.428B |
March 31, 2023 | 1.678B |
December 31, 2022 | 1.384B |
September 30, 2022 | 2.398B |
June 30, 2022 | 2.542B |
March 31, 2022 | 3.033B |
December 31, 2021 | 3.640B |
September 30, 2021 | 2.434B |
June 30, 2021 | 2.810B |
March 31, 2021 | 3.532B |
December 31, 2020 | 4.230B |
September 30, 2020 | 6.557B |
June 30, 2020 | 7.071B |
March 31, 2020 | 7.086B |
December 31, 2019 | 7.079B |
September 30, 2019 | 7.014B |
June 30, 2019 | 7.055B |
March 31, 2019 | 6.190B |
December 31, 2018 | 6.188B |
September 30, 2018 | 5.811B |
June 30, 2018 | 5.703B |
March 31, 2018 | 5.773B |
December 31, 2017 | 4.551B |
Date | Value |
---|---|
September 30, 2017 | 4.615B |
June 30, 2017 | 3.978B |
March 31, 2017 | 3.807B |
December 31, 2016 | 4.587B |
September 30, 2016 | 4.249B |
June 30, 2016 | 4.153B |
March 31, 2016 | 4.202B |
December 31, 2015 | 3.919B |
September 30, 2015 | 3.609B |
June 30, 2015 | 3.627B |
March 31, 2015 | 3.570B |
December 31, 2014 | 2.942B |
September 30, 2014 | 2.878B |
June 30, 2014 | 2.636B |
March 31, 2014 | 2.271B |
December 31, 2013 | 2.345B |
September 30, 2013 | 1.984B |
June 30, 2013 | 1.854B |
March 31, 2013 | 1.864B |
December 31, 2012 | 1.880B |
September 30, 2012 | 1.846B |
June 30, 2012 | 1.875B |
March 31, 2012 | 1.669B |
December 31, 2011 | 1.728B |
September 30, 2011 | 1.685B |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
1.360B
Minimum
Sep 2023
7.086B
Maximum
Mar 2020
3.888B
Average
3.033B
Median
Mar 2022
Cash from Operations (TTM) Benchmarks
Eli Lilly and Co | 4.240B |
Bristol-Myers Squibb Co | 13.86B |
AbbVie Inc | 22.84B |
Amgen Inc | 8.471B |
Regeneron Pharmaceuticals Inc | 4.594B |